The Potential Benefit of a Novel Urine Biosensor Platform for Lung Cancer Detection in the Decision-Making Process: From the Bench to the Bedside

<b>Background:</b> Lung cancer is the leading cause of cancer-related mortality worldwide. Lung cancer screening and early detection resulted in a decrease in cancer-specific mortality; however, it introduced additional dilemmas and adherence barriers for patients and providers. <b>Methods:</b> Innovations such as biomolecular diagnosis and biosensor-based technology improve the detection and stratification of high-risk patients and might assist in overcoming adherence barriers, hence providing new horizons for better selection of screened populations. <b>Conclusions:</b> In the present manuscript, we discuss some of the dilemmas clinicians are currently facing during the diagnosis and treatment processes. We further highlight the potential benefits of a novel biosensor platform for lung cancer detection during the decision making process surrounding lung cancer.